Blis Technologies

Blis Technologies is a New Zealand biotechnology company headquartered in Dunedin and focused on probiotics for the mouth and throat. Its core technology is based on selected strains of Streptococcus salivarius, a bacterium associated with the human oral microbiome. The company has developed branded probiotic products intended to support oral, throat and breath-related health, distributing them in formats such as lozenges, powders and chewing gum. The company was established in 2000 by microbiologist John Tagg, who left an academic position at the University of Otago in August of that year to commercialize research into bacteria and their potential effects on human health and hygiene. Tagg's interest in the subject was influenced by his experience with rheumatic fever during childhood and his subsequent efforts to investigate ways of countering disease-related bacteria. Blis Technologies was formed to translate this research into consumer health products. Its first major commercial product was ThroatGuard, introduced in 2002 and formulated with the BLIS K12 strain. The product helped establish the company's focus on oral and throat probiotics. The BLIS K12 platform was later adapted into additional products, including ToddlerProtect, a powder intended for children and infants, TravelGuard for travelers, and FreshBreath, introduced in 2005 for breath-freshness applications. These products extended the company's use of the same underlying probiotic research across different consumer needs and delivery formats. Blis Technologies subsequently expanded beyond BLIS K12 with BLIS M18, a Streptococcus salivarius strain developed for oral-care applications associated with tooth decay and periodontal health. Introduced to the New Zealand market in 2012 under the HealthyTeeth brand, BLIS M18 became the company's second major proprietary probiotic platform. The company has described clinical research as supporting the strain's role in promoting oral-cavity health, although individual product claims and regulatory treatment vary by market. The company's proprietary bacterial strains have also been protected through intellectual property. Blis Technologies has been associated with a world-first patent covering its selected oral-bacteria strain. In 2011, BLIS K12 received Generally Recognized as Safe status in the United States, allowing its use as a food additive under the relevant regulatory framework. The company has marketed its products internationally, while retaining its operational base in New Zealand. Blis Technologies has received recognition for its commercial and innovation activities, including a 2010 Frost & Sullivan Global Entrepreneurship award and Deloitte's recognition of the company as New Zealand's Fastest Growing Mature Business in 2016. Its public-company identity and international distribution distinguish it from a single-product supplement label: Blis Technologies operates as a specialist probiotic developer with a portfolio centered on oral microbiology, strain research and consumer health formulations.

Blis Technologies emerged from microbiological research conducted by John Tagg, a University of Otago microbiologist whose work examined bacteria found in diets and their possible effects on personal hygiene and human health. Tagg's interest in disease prevention was shaped in part by having contracted rheumatic fever at the age of 12. As a young scientist, he pursued ways of understanding and countering bacteria associated with illness. In August 2000, Tagg left his academic position at the University of Otago and established Blis Technologies in Dunedin. The company's purpose was to commercialize selected beneficial bacteria, particularly strains of Streptococcus salivarius associated with the mouth and throat. Rather than developing conventional pharmaceutical medicines, Blis Technologies built a biotechnology and consumer-health business around proprietary probiotic strains, intellectual property and branded delivery formats. The company's first significant commercial product was ThroatGuard, launched in 2002 with the BLIS K12 strain. This product established the company's central market proposition: using an oral probiotic in a convenient consumer format for throat-related health. The BLIS K12 platform was later used in products aimed at different audiences and occasions. ToddlerProtect was developed as a powder suitable for children and infants, while TravelGuard was introduced in 2006 for travelers exposed to airborne germs. FreshBreath, announced in September 2005, applied the same broad oral-health concept to breath freshness. Blis Technologies continued to broaden its science and product portfolio through BLIS M18, another Streptococcus salivarius strain. The strain was developed for oral-care applications involving bacteria associated with tooth decay and periodontal disease. It entered the New Zealand market in October 2012 under the HealthyTeeth brand. The company's materials and referenced clinical work have presented BLIS M18 as a probiotic intended to promote oral-cavity health. Regulatory and intellectual-property developments helped support the company's commercialization strategy. Blis Technologies has been associated with a world-first patent for its selected oral-bacteria strain. In 2011, BLIS K12 received U.S. Generally Recognized as Safe status, enabling its use as a food additive under the relevant U.S. framework. The company has sold products internationally in forms including lozenges, powders, gum and other formats, while remaining headquartered in Dunedin. The company has also received external recognition. Its oral-probiotic innovation and entrepreneurship were recognized with a 2010 Frost & Sullivan Global Entrepreneurship award. Deloitte later named Blis Technologies New Zealand's Fastest Growing Mature Business for 2016. Blis Technologies is publicly listed on the New Zealand Stock Exchange and has developed from a university-linked biotechnology venture into an international specialist in oral and throat probiotic products. Public reference material does not provide enough information here to document a complete current executive roster, ownership structure or detailed financial history.

1. 2016Deloitte growth recognition

   Deloitte recognized Blis Technologies as New Zealand's Fastest Growing Mature Business.

   Source
2. 2012HealthyTeeth introduced

   The company launched BLIS M18 in New Zealand under the HealthyTeeth brand for oral-health applications.

   Source
3. 2011BLIS K12 receives U.S. GRAS status

   BLIS K12 received Generally Recognized as Safe status for use as a food additive in the United States.

   Source
4. 2010Frost & Sullivan entrepreneurship recognition

   The company received Frost & Sullivan's Global Entrepreneurship award.

   Source
5. 2006TravelGuard launched

   TravelGuard expanded the BLIS K12 portfolio toward traveler-focused use.

   Source
6. 2005FreshBreath announced

   Blis Technologies added FreshBreath for breath-freshness and oral-care use.

   Source
7. 2002ThroatGuard reaches the market

   The company launched its first oral probiotic, ThroatGuard, containing the BLIS K12 strain.

   Source
8. 2000Blis Technologies founded

   John Tagg left the University of Otago in August and established Blis Technologies in Dunedin to commercialize oral-probiotic research.

   Source

Specialist developer of scientifically researched oral and throat probiotics.

• BLIS K12Oral and throat probiotic strain2002

  BLIS K12 is a proprietary Streptococcus salivarius strain used in Blis Technologies products for mouth and throat applications. It underpins the company's first major commercial product, ThroatGuard, and has also been formulated in products such as ToddlerProtect, TravelGuard and FreshBreath. The strain received U.S. GRAS status in 2011.

• BLIS M18Oral-health probiotic strain2012

  BLIS M18 is a Streptococcus salivarius strain developed for oral-care applications involving bacteria associated with tooth decay and periodontal disease. It was introduced to the New Zealand market in 2012 through the HealthyTeeth brand. Blis Technologies has associated the strain with clinical research concerning oral-cavity health.

• ThroatGuardThroat probiotic lozenge2002

  ThroatGuard was Blis Technologies' first marketed oral-probiotic product. Introduced in 2002, it contains BLIS K12 and represents the company's original consumer application of its selected Streptococcus salivarius research for throat-related health.

• ToddlerProtectChildren's probiotic powder

  ToddlerProtect adapted the BLIS K12 platform into a powder format intended for children and infants. It extended the company's oral-probiotic proposition beyond lozenges and into a format designed for younger consumers.

• TravelGuardTravel-oriented oral probiotic2006

  TravelGuard was introduced as a BLIS K12 product for travelers concerned about exposure to airborne germs. Its positioning applied the company's oral-probiotic technology to travel-related consumer needs.

• FreshBreathBreath-freshness probiotic2005

  FreshBreath was announced in 2005 as an oral-probiotic product intended to promote and maintain fresher breath. It broadened Blis Technologies' applications from throat-focused products to everyday oral-care use.

• HealthyTeethOral-health probiotic product2012

  HealthyTeeth is the brand under which Blis Technologies introduced BLIS M18 to the New Zealand market in 2012. It targets oral-health concerns connected with tooth decay and periodontal disease and is supported by the company's cited clinical research on the BLIS M18 strain.

• 2012Expansion into BLIS M18 oral-care productsProduct launch

  The company sought to expand beyond throat-focused BLIS K12 applications into oral-health areas associated with tooth decay and periodontal disease.

  What changed. Blis Technologies introduced BLIS M18 to New Zealand through the HealthyTeeth brand.

  Aftermath. The launch added a second major probiotic strain and broadened the company's oral-health portfolio.

  Source
• 2002Commercial launch of ThroatGuardProduct launch

  Blis Technologies needed a consumer product through which to commercialize its selected oral-bacteria research.

  What changed. The company launched ThroatGuard, an oral probiotic containing BLIS K12.

  Aftermath. ThroatGuard established the company's initial commercial category and became the foundation for later BLIS K12 products.

  Source
• 2000Transition from academic research to commercial biotechnologyStrategy

  John Tagg's research into oral bacteria and human health provided the basis for creating a company rather than continuing the work solely within an academic setting.

  What changed. Tagg left the University of Otago in August 2000 and founded Blis Technologies in Dunedin to develop and commercialize selected probiotic strains.

  Aftermath. The decision created a specialist biotechnology company centered on oral and throat probiotics and led to the later commercialization of BLIS K12 products.

  Source

• 2016Deloitte recognizes Blis Technologies as New Zealand's fastest-growing mature business

  Deloitte recognized the company in its New Zealand business awards as the Fastest Growing Mature Business.

  Other
  Source
• 2012HealthyTeeth launched with BLIS M18

  Blis Technologies introduced BLIS M18 to the New Zealand market through HealthyTeeth, targeting oral health areas connected with tooth decay and periodontal disease.

  Product launch
  Source
• 2011BLIS K12 receives U.S. GRAS status

  BLIS K12 obtained Generally Recognized as Safe status in the United States, supporting its use as a food additive within the applicable regulatory framework.

  Regulation
  Source
• 2006TravelGuard added to the product portfolio

  The company introduced TravelGuard, a BLIS K12 product positioned for travelers concerned about exposure to airborne germs.

  Product launch
  Source
• 2005FreshBreath introduced for breath-freshness applications

  Blis Technologies announced FreshBreath, extending its oral-probiotic product range toward breath maintenance.

  Product launch
  Source
• 2002Blis Technologies launches ThroatGuard with BLIS K12

  The company brought its first oral probiotic product to market, using the BLIS K12 strain in a throat-health formulation.

  Product launch
  Source

1. Blis Technologies
2. Blis Technologies official website